Optimizing lenalidomide therapy in renal impairment: analysis of renal response in the prospective REMNANT study in transplant-eligible newly diagnosed multiple myeloma

1

Renal impairment is a significant prognostic factor in multiple myeloma, reducing overall survival even after adjusting for comorbidities.
2

Rapid renal recovery is crucial for improved clinical outcomes in multiple myeloma patients, with early serum-free light chain reduction being a key determinant.
3

The REMNANT study evaluates the safety and efficacy of higher-dose lenalidomide in transplant-eligible newly diagnosed multiple myeloma patients with renal impairment.
4

Patients with eGFR ≥30 mL/min/1.73m2 received 25 mg/day lenalidomide, while those with eGFR <30 mL/min/1.73m2 received 15 mg/day during induction therapy.
5

The study aims to assess renal and overall response rates across different renal function groups after four cycles of bortezomib, lenalidomide, and dexamethasone.

Blood Cancer Journal

by Frida Bugge Askeland, Vilhelm Hauge Bugge, Anne-Marie Rasmussen, Anna Lysén, Einar Haukås, Magnus Moksnes, Anette L. Eilertsen, Galina Tsykunova, Birgitte Dahl Eiken, Nils Morten Leknes, Jürgen Rolke, Vidar Stavseth, Eivind Samstad, Randi Fykse Hallstensen, Damian Szatkowski, Ariane Aasbø Hansen, Anita Smith Nilsen, Tobias S. Slørdahl, Pegah Abdollahi, Fredrik Schjesvold
December 22, 2025

1